Trial Profile
VEDO-PREDIRESP Project: Value of Pharmacokinetic Assays (Vedolizumab and Anti-vedolizumab Antibody) in the Prediction of Induction and Maintenance Therapeutic Response in Crohn's Disease
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 19 Jun 2023
Price :
$35
*
At a glance
- Drugs Vedolizumab (Primary)
- Indications Crohn's disease
- Focus Pharmacokinetics
- Acronyms VEDO-PREDIRESP
- 13 Jun 2023 Status changed from recruiting to discontinued.
- 07 Feb 2023 Planned primary completion date changed from 1 Jul 2022 to 1 Jun 2023.
- 20 Sep 2021 Planned End Date changed from 1 Jun 2022 to 1 Jun 2023.